Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Issue title: Biomarkers for Ovarian Cancer: New Technologies and Targets to Address Persistently Unmet Needs
Guest editors: Michael A. Tainskyx and Anna Lokshiny
Article type: Research Article
Authors: Nowosinska, Ewa | Avril, Stefanie | Murray, Iain | Szyszko, Teresa | Avril, Norbert; *
Affiliations: Department of Nuclear Medicine, Barts Cancer Institute, Queen Mary University of London, London, UK | [x] Center for Molecular Medicine and Genetics, Wayne State University School of Medicine, 540 East Canfield Avenue, Detroit, MI, USA | [y] University of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh, PA, USA
Correspondence: [*] Corresponding author: Norbert Avril, M.D., Department of Nuclear Medicine, Barts Cancer Institute, Queen Mary University of London, West Smithfield (QE II), London EC1A 7BE, United Kingdom. Tel.: +44 20 346 55922; Fax: +44 20 346 56900; E-mail: n.e.avril@qmul.ac.uk.
Abstract: In the clinical setting the vast majority of positron emission tomography (PET) procedures use the glucose analogue F-18 fluorodeoxyglucose (FDG) to visualize the increased glucose consumption of malignant lesions. Co-registered PET/CT has improved the diagnostic accuracy compared to either imaging procedure alone, particularly in ovarian cancer. FDG-PET/CT demonstrates primary malignant ovarian tumors; however, it is often unable to accurately differentiate between benign and malignant pelvic masses and to visualize borderline ovarian tumors. FDG-PET/CT has a suggested role for staging, by improving treatment planning in individual cases, but it is particularly helpful in the setting of disease recurrence when CA125 tumor marker levels are rising and conventional imaging (CT or MR) is inconclusive or negative. The aim of this review is to demonstrate the value of FDG-PET-CT in diagnosis and management of patients with ovarian malignancies, outlining its advantages and limitations.
Keywords: PET, FDG-PET, PET/CT, ovarian cancer, diagnosis, staging, treatment monitoring
DOI: 10.3233/CBM-2011-0219
Journal: Cancer Biomarkers, vol. 8, no. 4-5, pp. 167-175, 2011
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl